Biosceptre

Cambridge, United Kingdom · Founded 2004 · Privately Held (backing)

Developer of chimeric antigen receptor T-cell therapy and antibody-based immune therapeutics designed to treat cancer. Biosceptre is based in Cambridge, United Kingdom and was founded in 2004. Its last reported valuation was $432 million in Feb 2024. It has raised $52.8 million.

Last reported valuation
$431.9M
Oct 2026
Priced at
—
Total raised
$52.8M
Last round
—

Who backs Biosceptre?

5 investors
InvestorType
Innovate UKOther
Norcliffe CapitalVenture capital
Jungle Capital—
McKenny-McFarlane Capital—
Tuspark Science and Technology Service Group—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Biosceptre investors

5 investors are on record for Biosceptre, including Innovate UK, Norcliffe Capital, Jungle Capital and McKenny-McFarlane Capital.

Free account
More of Biosceptre with a free account
  • ·Watch Biosceptre: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 5 firms already write checks for companies like Biosceptre. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View